Tolerance Bio Licenses NeoImmuneTech’s NT-I7 for Thymic Immune Restoration

Company: Tolerance Bio · Event Type: License Agreement · Licensor: NeoImmuneTech · Product: Efineptakin Alfa (NT-I7) · Mechanism: Long-Acting IL-7 Fusion Protein · Announcement Date: August 19, 2026 Summary Tolerance Bio licensed efineptakin alfa, also known as NT-I7, from NeoImmuneTech for certain thymus-related indications in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal